Nestle is investing 20 million euros in a joint venture with Enterome SA to develop microbiome-based diagnostics for inflammatory bowel and liver diseases.
Evelo BioSciences and Epiva Biosciences will combine efforts to become a leading immuno-microbiome platform company in the U.S.
While Seres has seen explosive headcount growth over the past year, the company is planning for more. Seres is expanding its physical footprint in Cambridge and hiring more staff.
Nestle, famous for its coffee and chocolate, is stepping up investment in nutritional therapy, a business it believes will eventually generate annual sales of 10 billion Swiss francs ($10.5 billion). Greg Behar, chief executive of Nestle Health Science, told Reuters that the unit formed in 2011 already had revenue of more than 2 billion […]
CHICAGO–(BUSINESS WIRE)–A scientific paper published In the July issue of the prestigious peer-reviewed scientific Journal “Anticancer Research,” describes the properties of a food product that is reminiscent of the “super food for the third brain.” Japanese researchers from the universities of Tokushima and Kobe in Japan report the clinical results of treating patients with Chronic […]